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AbstrACt
Objectives To analyse the trends of amenable mortality 
rates (AMRs) in children over the period 2001–2015.
Design Time trend analysis.
setting Thirty-four member countries of the Organisation 
for Economic Co-operation and Development (OECD).
Participants Midyear estimates of the resident population 
aged ≤14 years.
Primary and secondary outcome measures Using data 
from the WHO Mortality Database and Nolte and McKee’s 
list, AMRs were calculated as the annual number of deaths 
over the population/100 000 inhabitants. The rates were 
stratified by age groups (<1, 1–4, 5–9 and 10–14 years). 
All data were summarised by presenting the average rates 
for the years 2001/2005, 2006/2010 and 2011/2015.
results There was a significant decline in children’s 
AMRs in the <1 year group in all 34 OECD countries from 
2001/2005 to 2006/2010 (332.78 to 295.17/100 000; 
%Δ −11.30%; 95% CI −18.75% to −3.85%) and from 
2006/2010 to 2011/2015 (295.17 to 240.22/100 000; 
%Δ −18.62%; 95% CI −26.53% to −10.70%) and a slow 
decline in the other age classes. The only cause of death 
that was significantly reduced was conditions originating 
in the early neonatal period for the <1 year group. The 
age-specific distribution of causes of death did not vary 
significantly over the study period.
Conclusions The low decline in amenable mortality rates for 
children aged ≥1 year, the large variation in amenable mortality 
rates across countries and the insufficient success in reducing 
mortality from all causes suggest that the heath system 
should increase its efforts to enhance child survival. Promoting 
models of comanagement between primary care and 
subspecialty services, encouraging high-quality healthcare 
and knowledge, financing universal access to healthcare and 
adopting best practice guidelines might help reduce amenable 
child mortality.
IntrODuCtIOn
The health of children and adolescents is an 
important goal for every society, both because 
they are vulnerable and because diseases 
can affect their quality of life. Measures for 
protecting and improving children’s and 
adolescents’ health will yield economic and 
social benefits beyond improved health 
outcomes. Indeed, young people have the 
potential to affect the health of future popu-
lations as well as global economic develop-
ment unless timely and effective strategies are 
put into place.1 2 
For the adoption of new strategies and 
the planning of interventions, information 
on the leading causes of death is essential. 
Many studies have analysed the mortality 
rates and have identified the main causes of 
death of children in specific countries3 or 
areas.4 Studies have demonstrated that many 
different factors contribute to child and 
adolescent mortality,5 including biological 
and psychosocial,6 socioeconomic status,7 8 
environmental and behavioural factors.9 In 
the landscape described, the mortality 
burden conditioned by the performance 
of the healthcare system has not been well 
strengths and limitations of this study
 ► This is the first study to analyse trends in child mor-
tality amenable to healthcare.
 ► Thirty-four Organisation for Economic Co-operation 
and Development countries were included in the 
analyses to provide a thorough depiction of amena-
ble child mortality in high-income economies.
 ► Mortality was not disaggregated by ethnicity or so-
cioeconomic characteristics.
 ► Making international comparisons is difficult due to 
variations in birth registration laws and death certi-
fication practices.
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investigated. Although there is no indicator that is able to 
compressively reflect the performance of the healthcare 
system, a suitable measurement seems to be the concept 
of amenable mortality.
Amenable mortality is defined as deaths that, in the 
light of medical knowledge and technology at the time of 
death, could be prevented by timely access to good quality 
care. The concept of mortality amenable to healthcare 
finds its origins in the evolution of the concept of avoid-
able mortality, developed by Rutstein et al10, who created 
a list of conditions that were considered either treatable 
or preventable through healthcare services given the 
current medical knowledge and technology. Rutstein was 
the first to introduce the term amenable mortality, differ-
entiating between causes that are responsive to medical 
intervention through treatment and secondary/tertiary 
prevention actions (eg, cervical cancer, hypertensive 
disease or appendicitis) and causes responsive to actions 
beyond healthcare services (preventable conditions such 
as lung cancer and liver cirrhosis).
In recent years, the concept of amenable mortality has 
been used as a potential indicator of the performance of 
healthcare systems by several countries. The amenable 
mortality has been chosen as indicator in the UK National 
Health Service Outcomes Framework for 2011–201211 
and in Australian and New Zealand Atlas of Avoidable 
Mortality 1997–200112 or in European Community Atlas of 
‘Avoidable Death’.13 Amenable mortality indicators have 
also been used to report on spatial and temporal distribu-
tions and variations in health system performance across 
countries,14–20 as well as across subnational entities,12 21–25 
socioeconomic status, ethnic groups and sex.14 24 26 27 Most 
of these studies did not assess amenable mortality across 
ages in different populations and did not focus on child 
and adolescent age classes.
According to the WHO, an estimated 6.3 million chil-
dren under the age of 15 years died in 2017 (117 000 in 
the Organisation for Economic Co-operation and Devel-
opment (OECD) region). A total of 5.4 million of these 
children were under the age of 5 years, and 2.5 million 
died within the first month of life. More than half of these 
early child deaths were due to conditions that could be 
prevented or treated with access to simple, affordable 
interventions and were, consequently, amenable.2
The purpose of this study was to analyse the trends of 
amenable child mortality rates in 34 OECD countries 
from 2001 to 2015 and to evaluate the pattern across age 
classes.
MAterIAls AnD MethODs
This descriptive study was conducted using secondary 
data from 34 OECD countries during the period from 
2001 to 2015. Mexico and Turkey, although members 
of the OECD, were not included in the analysis because 
these countries are not listed among high-income econo-
mies in the World Development Indicators dataset (gross 
national income per capita ≥$12 056 for fiscal year 2019)28 
and had limited data availability. The mortality and popu-
lation data came from the WHO Mortality Database,29 
which comprises deaths registered in national vital regis-
tration systems, with the underlying causes of death coded 
according to the International Classification of Diseases; 
no permission is required from the WHO if data are used 
for non-commercial purposes. If reference populations 
were not available in the WHO Mortality Database, the 
data were extracted from UN data.30 The country-level 
data availability is presented in online supplementary file 
1.
The causes of death amenable to healthcare were 
selected by means of the list proposed by Nolte and 
McKee14 31 and used in a working paper by the OECD to 
generate estimates of amenable mortality for 31 coun-
tries.15 This list includes a selected number of conditions 
that are treatable based on the clinical effectiveness of 
existing medical interventions. The age limit for amenable 
deaths is set at 75 years for most conditions, such as cancer 
and cardiovascular diseases, but the age limit for some 
diseases (ie, whooping cough, measles, intestinal infec-
tions and respiratory diseases other than pneumonia/
influenza) is set at 14 (see online supplementary file 2 
for Nolte and McKee’s full list). The aggregation of the 
causes of death operated in the WHO Mortality Database 
prevents the use of the list of amenable deaths currently 
adopted by Eurostat.32
For each country, the amenable mortality rates were 
calculated as the annual number of deaths in the popu-
lation aged 0–14 years per 100 000 inhabitants. The rates 
were stratified by the age groups adopted in the WHO 
Mortality Database (<1, 1–4, 5–9 and 10–14 years) and 
by the 33 disease categories defined by Gay et al.15 Due 
to the instability in the estimates of the annual amenable 
mortality rates, especially for small population countries, 
all data were summarised by presenting the average rates 
for the years 2001/2005, 2006/2010 and 2011/2015. 
The statistical significance of the percentage changes 
between these time periods was assessed by using the 
formula suggested by Hildebrandt et al.33 Data interpre-
tation focused on the countries that showed significant 
percentage changes over the entire study period (ie, 
both between 2001/2005 and 2006/2010 and between 
2006/2010 and 2011/2015). Differences in the ranking 
of age-specific causes of death between time periods were 
evaluated with the Friedman test.
All data were analysed using the Stata software package, 
V.15. The significance level was set at. 05.
ethics statement
This descriptive study involved aggregate data that exist 
in the public domain, where it is not possible to iden-
tify individuals from the information provided. For this 
reason, this research did not require ethical approval.
Patient and public involvement
Patients and the public were not involved in the design or 
planning of the study.
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results
All-cause amenable child mortality rates
The results of the trend analyses conducted over the 
5-year periods 2001/2005, 2006/2010 and 2011/2015 are 
presented in figure 1 and in online supplementary file 
3. The amenable mortality rate of the OECD population 
with <1 year dropped significantly from 2001/2005 to 
2006/2010 (332.78 to 295.17 per 100 000, %Δ=−11.3%) 
and from 2006/2010 to 2011/2015 (295.17 to 240.22 
per 100 000, %Δ=−18.6%). Contrary to the OECD rate 
of children aged <1 year, in the population aged ≥1 year, 
the overall OECD rate did not decrease significantly. 
From 2001/2005 to 2006/2010 and from 2006/2010 to 
2011/2015, the mortality rates decreased by 13.4% and 
13.0%, respectively, in the 1–4 years age group; by 11.9% 
and 11.3% in the 5–9 years age group; and by 13.5% and 
13.1% for the 10–14 years age group. In 2011/2015, the 
OECD rate was 4.73 per 100 000 for the 1–4 years age 
group, 2.02 per 100 000 for the 5–9 years age group and 
2.16 per 100 000 for the 10–14 years age group.
Cause-specific child mortality rates
When we examined the distribution of cause-specific 
mortality rates across multiple age groups and study 
periods, no statistically significant variations in the OECD 
population were found. The only exception was a signif-
icant decrease in deaths in the first year of life for condi-
tions originating in the early neonatal period (2001/2005 
to 2006/2010: 266.3 to 239.8 per 100 000, %Δ=−9.9%; 
2006/2010 to 2011/2015: 239.8 to 193.8 per 100 000, 
%Δ=−19.2%) (see online supplementary file 4).
Globally, for the years 2001/2005, 2006/2010 and 
2011/2015, there were no significant differences in the 
age-specific percentage distribution of causes of death 
(<1 year: Friedman test (p)=0.955 (0.372); 1–4 years: 
0.864 (0.607); 5–9 years: 0.470 (0.740); 10–14 years: 1.773 
(0.398)). As shown in table 1, the three leading causes of 
death by age groups over the 15 year study period were 
the following: conditions originating in the early neonatal 
period, congenital cardiovascular anomalies and pneu-
monia for children aged <1 year and congenital cardio-
vascular anomalies, leukaemia and respiratory diseases 
(excluding pneumonia/influenza) for all other age 
groups.
Country-specific amenable child mortality rates
As shown in figure 1 and online supplementary file 3, the 
amenable mortality rate for the population aged <1 year 
dropped significantly over the entire study period in 15 
countries (USA, Israel, Japan, South Korea, Czechia, 
Estonia, Germany, Italy, Latvia, Hungary, Poland, Spain, 
Austria, UK and Australia). In addition to the decrease 
in conditions originating in the early neonatal period, 
other causes contributed to a significant reduction in 
mortality for some of these countries: septicaemia, pneu-
monia and nephritis/nephrosis in the USA, septicaemia 
in Poland and congenital cardiovascular anomalies in 
Japan and Spain. See online supplementary file 4 for 
country-specific and cause-specific mortality rates in 
the <1 year population.
Although the overall OECD rate did not decrease 
significantly in the population aged ≥1 year, some coun-
try-specific data exhibited significant trends (figure 1). 
However, no country showed a significant linear decline 
in mortality over the entire study period for all age groups 
(figure 1).
DIsCussIOn
In this time trend analysis, we found a significant decline 
in amenable child mortality rates for the <1 year age 
group in the 34 OECD countries between 2001/2005 and 
2011/2015 and a slow decline in the other age groups. 
These results confirm the trend shown by previous studies 
conducted on six OECD countries that had been selected 
to provide a variety of forms of healthcare delivery 
between 1956 and 198021 and highlight that policies to 
reduce amenable mortality rates are still needed, even 
in settings where the quality of medical services and 
resources is high.
These results are driven by the fact that the only signifi-
cantly reduced cause of death was conditions originating 
in the early neonatal period in the <1 year group. Surpris-
ingly, the decline was not more pronounced among 
countries with higher mortality in 2001/2005, indicating 
that continued gains in child survival occurred both in 
low-mortality and high-mortality countries. The most 
representative countries are Japan, which showed an 
improvement in its performance despite starting from low 
values in 2001/2005, and Hungary and the USA, which 
showed high amenable mortality rates in 2001/2005.
The results concerning country-specific amenable 
child mortality rates showed that the reductions in the 
age-specific rates were not evenly distributed across 
OECD countries. There was not a single cause for which 
the age-specific mortality rates declined in the countries 
studied, and the success in reducing mortality rates was 
not consistent for all causes. These achievements corrob-
orate another of our results, highlighting that the causal 
distribution of the age-specific mortality rates did not vary 
over the period examined and that, namely, the condi-
tions originating in the early neonatal period, congenital 
cardiovascular anomalies, pneumonia, leukaemia and all 
respiratory diseases (excluding pneumonia/influenza) 
were consistently top ranked. Because these are the main 
causes related to chronic disorders and pathologies that 
require acute care delivered quickly, our results suggest 
that the models of care for children should be revised. 
Sidebotham5 has argued that child diseases might broadly 
be divided into chronic (eg, leukaemia) and acute 
diseases (eg, pneumonia) and that a single model cannot 
be proposed but each needs a different, although inter-
connected, health system solution.
Wolfe34 highlights that the presence of children with 
chronic disorders requires substantial changes from a 
hospital-centric model to a model in which primary care 
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Figure 1 Yearly amenable mortality rates (per 100 000) for ages <1 (A), 1–4 (B), 5–9 (C) and 10–14 (D) in 34 Organisation for 
Economic Co-operation and Development countries, 2001/2005, 2006/2010 and 2011/2015 (see online supplementary file 
1 for country-level data availability). *Percentage decrease is statistically significant (p<0.05). AT, Austria; AU, Australia; BE, 
Belgium; CA, Canada; CL, Chile; CZ, Czechia; CH, Switzerland; DE, Germany; DK, Denmark; EE, Estonia; ES, Spain; FI, Finland; 
FR, France; GR, Greece; GB, UK; HU, Hungary; IL, Israel; IS, Iceland; IE, Ireland; IT, Italy; JP, Japan; KR, Republic of Korea; 
LT, Lithuania; LU, Luxembourg; LV, Latvia; NL, The Netherlands; NO, Norway; NZ, New Zealand; PL, Poland; PT, Portugal; SE, 
Sweden; SI, Slovenia; SK, Slovakia; US, USA. 
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Table 1 Percentage distribution of the top 10 causes of death amenable to healthcare in children in 34 OECD countries, years 
2001/2005, 2006/2010 and 2011/2015
Cause of death
2001/2005 2006/2010 2011/2015
Rank % Rank % Rank %
<1 year (n=190 169.5) (n=175 008) (n=105 210.5)
Conditions originating in the early neonatal period #1 80.02 #1 81.25 #1 80.69
Congenital cardiovascular anomalies #2 14.38 #2 13.15 #2 14.55
Pneumonia #3 1.82 #3 1.53 #3 1.30
Septicaemia #4 1.50 #4 1.39 #4 1.04
Intestinal infections other than typhoid, diphtheria #7 0.27 #5 0.60 #5 0.72
Cerebrovascular diseases #6 0.51 #6 0.60 #6 0.38
Nephritis and nephrosis #5 0.54 #7 0.49 #7 0.25
Leukaemia #8 0.21 #8 0.26 #8 0.24
Epilepsy #9 0.17 #9 0.17 #9 0.23
Whooping cough #11* 0.11 #12* 0.10 #10 0.19
Other causes – 0.46 – 0.46 – 0.39
1–4 years (n=14 438) (n=12 738) (n=8491.5)
Congenital cardiovascular anomalies #1 25.67 #1 23.63 #1 25.21
Leukaemia #3 14.55 #3 13.99 #2 14.99
All respiratory diseases, excluding pneumonia/
influenza
#2 15.60 #2 16.79 #3 14.25
Pneumonia #4 12.35 #4 12.20 #4 12.24
Epilepsy #7 5.16 #7 5.50 #5 7.20
Septicaemia #5 7.57 #5 8.18 #6 6.88
Conditions originating in the early neonatal period #6 5.59 #6 5.60 #7 5.06
Intestinal infections other than typhoid and 
diphtheria
#9 2.45 #9 3.05 #8 3.98
Cerebrovascular diseases #8 3.86 #8 4.13 #9 3.38
Influenza #10 2.16 #10 1.92 #10 2.39
Other causes – 5.05 – 5.00 – 4.42
5–9 years (n=7705) (n=6706) (n=4541)
Leukaemia #1 31.72 #1 28.35 #1 27.31
All respiratory diseases, excluding pneumonia/
influenza
#3 12.91 #2 16.28 #2 13.87
Congenital cardiovascular anomalies #2 14.91 #3 13.67 #3 13.12
Epilepsy #5 7.81 #5 7.86 #4 10.37
Pneumonia #4 8.58 #4 7.90 #5 9.12
Cerebrovascular diseases #6 6.87 #6 7.13 #6 6.69
Septicaemia #7 5.15 #7 5.67 #7 5.26
Influenza #9 1.66 #8 2.54 #8 2.97
Conditions originating in the early neonatal period #8 2.25 #9 2.48 #9 2.80
Intestinal infections other than typhoid and 
diphtheria
#13† 0.87 #12† 1.25 #10 2.00
Other causes – 7.26 – 6.87 – 6.47
10–14 years (n=9109) (n=7579) (n=4921)
Leukaemia #1 31.30 #1 30.01 #1 30.24
All respiratory diseases, excluding pneumonia/
influenza
#3 13.66 #2 15.28 #2 13.66
Continued
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and secondary care providers and public health services 
work closely together. Models of comanagement are 
essential to promote ongoing communication and coor-
dination between primary care and subspecialty services. 
It would be inefficient for subspecialists to provide 
primary care, and ineffective for primary care providers to 
attempt to stay abreast of the latest therapies for chronic 
diseases. Because the majority of chronic illness care is 
performed within the primary care setting and because 
primary care physicians spend a considerable amount of 
time treating chronic illness, primary care should play a 
central role in the overall coordination and continuity of 
people’s care providing greater access to specialists and 
more timely follow-up care after emergency room visits.35 
The few studies evaluating this new approach to work 
showed an improvement in child survival,36–38 and thus 
traced a possible path to improve amenable mortality 
from chronic diseases.
Sidebotham and Mackenbach judge as determinants 
of amenable mortality in acute diseases the universal 
access to healthcare and the presence of professionals 
with appropriate training.5 18 The relevance of access 
may at least partially explain our results in some coun-
tries. For example, in Chile, where the mortality rate of 
pneumonia was consistently high for the <1 year group, 
the healthcare system replicates class inequalities. Studies 
have identified and tracked several important inequalities 
in the burden of infant mortality for infectious diseases 
by socioeconomic level in Chile, showing that this gap 
is discriminatory because disadvantaged households 
underuse healthcare services (due to social or economic 
exclusion).39 40 In Slovakia, where also the mortality rate 
of pneumonia was high for the <1 year group, social 
health insurance system formally covers all residents and 
has a benefit package that all insurance companies must 
provide for their insured. In theory, the insurance system 
is thus designed to provide everybody with the same 
benefit package, regardless of their health status, ability 
to pay or place of residence. In practice, coverage varies 
across the country, mainly because the supply of human 
resources (especially specialists and general practitioners 
(GPs)) is not adequate in all regions and districts, and 
sometimes providers are simply not available.41
The access to healthcare professionals with adequate 
training looks at the models of first contact between 
patients and clinicians and on their expertise. Although 
an international debate is open on the best pattern of 
paediatric primary care among a paediatrician-based 
system, a combined system or a system based on GPs/
family doctors,42 some authors highlight the importance 
of primary care paediatricians, especially because primary 
care paediatricians who look after children are likely to 
have more professional training and competencies than 
GPs, who often, receiving an insufficient or not existing 
or non-mandatory training, do not have capabilities to 
diagnose and treat a child in effective times.34 43 44
Supported by the specialised literature, the availability 
of high-quality healthcare and knowledge and the use 
of best practice guidelines are also determinants of 
amenable mortality.5 18 These determinants provide one 
possible explanation for our results, in particular for the 
reduction in mortality by conditions originating in the 
early neonatal period. Several lines of evidence support 
the hypothesis that neonatal intensive care has resulted 
in decreased mortality. Marked declines in neonatal and 
infant mortality rates are coincident with the introduc-
tion and progressive development of neonatal intensive 
care45 46 and with specific neonatal intensive therapeutic 
improvements.47–50 The second line of evidence regarding 
the effect of neonatal intensive care on infant mortality 
is the observation that low birthweight infants born in 
hospitals with tertiary-level neonatal intensive care units 
have lower mortality rates than infants born in hospitals 
without such units.51 52 Finally, a third line of evidence 
Cause of death
2001/2005 2006/2010 2011/2015
Rank % Rank % Rank %
Congenital cardiovascular anomalies #2 14.13 #3 12.17 #3 12.62
Epilepsy #5 7.73 #5 7.89 #4 10.36
Cerebrovascular diseases #4 8.12 #4 8.99 #5 9.08
Pneumonia #6 7.59 #6 6.73 #6 7.27
Septicaemia #7 4.17 #7 4.92 #7 4.29
Diabetes mellitus #8 2.49 #8 2.31 #8 1.97
Influenza #11‡ 1.15 #9 2.15 #9 1.77
Conditions originating in the early neonatal period #10 1.57 #11‡ 1.78 #10 1.52
Other causes – 8.09 – 7.78 – 7.21
*Abdominal hernia was ranked #10 in 2001/2005 (0.17%) and 2006/2010 (0.13%).
†Nephritis and nephrosis were ranked #10 in 2001/2005 (1.60%) and 2006/2010 (1.69%).
‡Nephritis and nephrosis were ranked #9 in 2001/2005 (1.79%) and #10 in 2006/2010 (1.91%).
OECD, Organisation for Economic Co-operation and Development.
Table 1 Continued 
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referring to improving high-risk obstetric care has been 
associated with decreases in neonatal mortality.46 53
Variations in child mortality exist even in countries 
where high-quality healthcare is available. Part of this vari-
ation may be due to a failure in implementing treatment 
protocols or evidence-based best practices tailored with 
the local conditions. This suggestion may provide some 
explanation of the mortality decrease in some countries, 
such as Hungary and Japan, which have supported the 
introduction of evidence-based protocols on routine 
newborn care and have trained nursery staff members on 
the protocols.54 55
Our study has the same limitations as all studies that 
use secondary data. It is undeniable that international 
variations in birth registration laws and practices and the 
process of death certification have the potential to bias 
the international comparisons of child mortality. Addi-
tionally, international comparisons of mortality rates are 
confounded by the various ways in which countries classify 
preterm infants near the threshold of viability.56–58 Consid-
ering these issues, our study only evaluates the trend of 
amenable mortality rates, and a comparison analysis was 
not performed. Also, although much of the literature 
assessing the contribution of healthcare to health focuses 
on mortality data, data on children may be of limited value 
because the number of deaths is small, making interpreta-
tion difficult. However, we believe that the small numbers 
were mitigated by the fact that our study analysed the 
rates and trajectories of multiple countries over a 15-year 
time period. Another limitation is that our analysis did 
not account for mortality disparities within countries 
that were attributable to ethnicity, race, socioeconomic 
status or geographic residence, since our data sources 
did not include this information. Evidence from the USA, 
for example, showed higher levels of amenable mortality 
among people disadvantaged in terms of race or socioeco-
nomic status.59 60 Considering that the perinatal mortality 
of the USA has a prevailing effect on premature births and 
that striking racial disparities persist, with African-Ameri-
cans exhibiting higher rates of preterm delivery than any 
other major racial/ethnic group,61 potentially large vari-
ations within populations may be concealed. Lastly, our 
study is based on the definition of amenable death in its 
original sense of mortality responsive to medical interven-
tion through treatment, although several countries, such 
as UK, Canada and Australia, have broadened definitions 
for their avoidable mortality indicators to include deaths 
from conditions avoidable through primary prevention. 
This broadened definition suggests that the models of 
care for children should be revised and that policies must 
be adopted in order to prevent specific causes of death 
before the point of reaching the healthcare system. These 
policies include population health interventions such as 
the obligation of physical activity during adolescence in 
schools or the taxation of tobacco and sugar-sweetened 
beverages.
Some preliminary conclusions can be drawn from 
this study. Over the 15-year period from 2001 to 2015, 
the amenable mortality rate in <1 year olds progressively 
declined in most OECD countries. Second, OECD countries 
had success in reducing mortality from conditions origi-
nating in the early neonatal period. Lastly, the low decline in 
amenable mortality rates for children aged ≥1 year, the high 
variation in amenable mortality rates across countries and 
the insufficient success in reducing mortality from all causes 
suggest that the heath system should increase its efforts to 
improve health outcomes for children.
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